NCT03239860View on ClinicalTrials.gov

Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

June 6, 2017

Primary Completion Date

November 14, 2018

Study Completion Date

November 14, 2018

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

GNbAC1 Monoclonal Antibody

Monthly IV

Trial Locations (12)

Unknown

Hospital, Sofia

Hospital, Zagreb

Hospital, Jihlava

Hospital, Tallinn

Hospital, Berlin

Hospital, Budapest

Hospital, Rome

Hospital, Warsaw

Hospital, Moscow

Hospital, Belgrade

Hospital, Barcelona

Hospital, Kharkiv

Sponsors

Lead Sponsor

GeNeuro SA
All Listed Sponsors
collaborator

Les Laboratoires Servier

UNKNOWN

collaborator

Worldwide Clinical Trials

OTHER

collaborator

Institut de Recherches Internationales Servier

OTHER

lead

GeNeuro SA

INDUSTRY